Strides Pharma Science Arm Gets Usfda Nod For Drug To Treat Overactive Bladder
Strides Pharma Science Friday Said Its Step-Down Wholly-Owned Subsidiary Has Received Approval From The Us Health Regulator For Solifenacin Succinate Tablets, Used To Treat Overactive Bladder.The Approved Product Is A Generic Version Of Vesicare Tablets Of Astellas Pharma Us, Inc.Strides Pharma Global, Singapore, Has Received Approval For Solifenacin Succinate Tablets, 5 Mg And 10 Mg, From The United States Food And Drug Administration (Usfda), Strides Pharma Science Said In A Regulatory Filing.Citing Iqvia Data, The Company Said The Us Market For Solifenacin Succinate Tablets, 5 Mg And 10 Mg Is Approximately Usd 820 Million.Strides Said The Product Will Be Manufactured At Alathur Facility In Chennai And Will Be Marketed By Strides Pharma In The Us Market.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
